BIONTECH SE SPON. ADRS 1
Commented by Carsten Mainitz on April 20th, 2021 | 07:10 CEST
BioNTech, SunMirror, Steinhoff - Great News!
Shortly before the finish line, the going gets tough again. Many athletes and those who have to really "bite" in the last few meters before a deadline are probably familiar with this feeling. Everyday life in the Corona pandemic is also becoming more exhausting. Now, with BioNTech's announcement that it will double weekly vaccine dose deliveries to around 5.1 million units from the end of May, there may be a breakthrough in achieving herd immunity in Germany in the next few months. It is not only good news for the Company's shareholders but everyone. Below we present two other companies whose shareholders should be very pleased. Let us surprise you!
Read
Commented by Nico Popp on April 20th, 2021 | 06:50 CEST
CureVac, BioNTech, PsyBio: Yesterday's game changers - and tomorrow's?
Vaccines against the coronavirus are changing everything. People who sat anxiously at home just a few weeks ago now dare to socialize again after their injection. Even if contact restrictions still apply - the feeling of being alive is different after the vaccination. German vaccine manufacturers, in particular, have used innovative mRNA technology to create vaccines that are largely scandal-free - and offer good protection. In the slipstream, new, innovative companies are already preparing to bring the next game changers to market. For investors, this can be a rewarding environment.
Read
Commented by André Will-Laudien on April 12th, 2021 | 08:30 CEST
BioNTech, Formycon, Psybio Therapeutics: A chance for normality?
It is a matter of course: The desire for normality! Things have not been normal over the last 12 months, which everyone is now feeling. Our society has had a lot to shoulder since the turn of the millennium. The extreme increase in radicalism, the emergence of dangerous dictators and incompetent politicians, the polarization of beliefs, the explosive development of wealth in shares and real estate owners with simultaneous global impoverishment, the excessive indebtedness of the states, and now, a worldwide pandemic of unimagined proportions. It takes a good deal of imagination to believe in a "normalization" and then a more philosophical question quickly arises: What does an economic reality with and after the pandemic look like?
Read
Commented by Nico Popp on March 23rd, 2021 | 14:00 CET
BioNTech, Marble Financial, Disney: Innovations that pay off
The stock market is where the future is traded. Groundbreaking innovations can completely change this future and provide investors with high returns from the very beginning. Examples include all investors who took an early stake in shares of Amazon or Alphabet. There are also currently a whole series of shares that stand for innovation. We present three stocks.
Read
Commented by Nico Popp on March 10th, 2021 | 09:27 CET
BioNTech, CureVac, Cardiol Therapeutics: Biotech rockets off the launchpad
We all know that health is the greatest good. But it is only the last year or so that we've become fully aware of the fact that everything changes during a pandemic. Work, family, leisure time - no area of life is not currently under the influence of Covid-19. But even if lockdown fatigue is slowly but surely setting in, investors should remain wide awake. In many sectors, the course is currently being set for the future - especially in the pharmaceutical and biotech industries. Reason enough to take a closer look at these three stocks.
Read
Commented by Nico Popp on March 9th, 2021 | 07:15 CET
BYD, BioNTech, Kleos Space: A new trend starts here
If you want to be successful on the stock market, you have to back those shares with prospects. Although an intact upward trend suggests that a story will be well received on the market, the fall height also increases with the price. Investors have recently had to experience this pain, especially with shares in the field of electromobility or hydrogen. Even vaccine hopefuls such as BioNTech have lost ground. Let us show you how the trend stocks are faring and which sector is only at the beginning of its trend!
Read
Commented by André Will-Laudien on March 2nd, 2021 | 11:15 CET
Q&M Dental, Pfizer, BioNTech, Teva: Watch out for these pharma picks!
The COVID pandemic has permanent surprises in store, which strongly influence our daily life. The province of Tyrol was sealed off entirely 2 weeks ago. The Czech Republic is being helped out with vaccine doses because the incidence figures are going through the roof. In Germany, hairdressers and DIY stores have been allowed to open again. Gradually, everyday life is returning to normal, but it will probably take some time before we regain the quality of life of the pre-Corona years. Let's take a closer look at various business models in the healthcare industry to get a feel for what's next.
Read
Commented by Nico Popp on February 4th, 2021 | 08:15 CET
BioNTech, Cardiol Therapeutics, Johnson & Johnson: biotech gems from the well-known to the unknown
If there's one industry that's rightfully making big profits these days, it's healthcare companies. The pandemic has kissed the industry awake. In addition to the current relevance around Covid treatment, test procedures, or even vaccinations, there is also a growing awareness that medical innovation depends on research. More and more investors are willing to push promising projects and the general conditions for this could not be better. There is a consensus in politics, society and business that health is the highest good.
Read
Commented by André Will-Laudien on December 1st, 2020 | 09:54 CET
Desert Gold, BioNTech, Vodafone - Healthier, Cleaner, Gold!
Asian stocks have recently faltered near their record highs, but the Nikkei, in particular, has experienced a grand rally of 15% in the last 4 weeks. Yesterday 30.11. is a popular settlement day for fund managers around the globe because from this date on you only have 1 month to clean the portfolio from unwanted components. In simple terms, stocks which ran poorly all year are likely to be sold and stocks that everyone's talking about and have performed well so far, tend to be topped up again. Among asset management experts, these measures are called "window dressing", i.e., perfecting the design of the viewing rooms in the form of a portfolio listing.
On the market as a whole, investors seem to be developing the view that the economic recovery will gain momentum next year, and this is driving some to liquidate their gold holdings - intended as a security investment - rather than to sell them. On the technical front, support for gold remains intact at around USD 1,750 to USD 1,770 an ounce. Silver continues to see massive interest near the psychological level of USD 22-23, the Technical Analysis tells us. Whether we can take this as a given at the end of the year remains to be seen; the pressure on precious metals prices is currently high.
Read
Commented by Stefan Feulner on November 25th, 2020 | 11:15 CET
Moderna, Triumph Gold, BioNTech - bet on winners!
Gold has not made it out - for the time being. Due to the decision of the Americans pro Joe Biden and the very successful developments regarding a vaccine against the coronavirus, the precious yellow metal went downhill for the time being. The correction may well continue a little further. However, in the past, these setbacks were lucrative with anti-cyclical entry opportunities. Therefore, one should use the time now to take a closer look at promising gold mines.
Read